Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape

The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Listen to this podcast with 2 experts discussing current gaps and clinical needs for patients with relapsed ES-SCLC, the scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC, the expanding role of antibody–drug conjugates (ADCs) and T-cell engagers in ES-SCLC including recent efficacy and safety data for B7-H3–directed ADCs such as ifinatamab deruxtecan (I-DXd) in ES-SCLC and the strengths and limitations of the available evidence. The experts synthesize this information along with their clinical experiences to illustrate how they are individualizing the care of patients with ES-SCLC based on patient-specific characteristics that influence the selection and sequencing of treatment with a case-based discussion. They close with a reminder of the importance of discussing ongoing trials of investigational B7-H3–directed ADCs and other therapies in ES-SCLC with the goal of continuing to improve outcomes for patients with this disease.